A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To evaluate the steady-state pharmacokinetics (PK) and confirm the dose of ritonavirboosted elvitegravir (GS-9137/r) in HIV-1 infected antiretroviral treatment-experienced adolescent subjects.

Critère d'inclusion

Human Innunodeficiency Virus (HIV-1) Infections

Liens

euctr
ictrp